Expression and functional activity of osteoprotegerin in human malignant gliomas

[1]  M. Weller,et al.  Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins , 2003, Glia.

[2]  J. Penninger,et al.  RANKL and RANK as novel therapeutic targets for arthritis. , 2003, Current opinion in rheumatology.

[3]  P. Croucher,et al.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. , 2003, Cancer research.

[4]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[5]  W. Cavenee,et al.  Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. , 2001, Journal of neurosurgery.

[6]  S. Kügler,et al.  Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. , 2001, Cancer research.

[7]  M. Weller,et al.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.

[8]  P. Kostenuik,et al.  Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. , 2001, Current pharmaceutical design.

[9]  I. Pollack,et al.  Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  B. Davidson,et al.  Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1 , 2000, The Journal of Immunology.

[11]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[12]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[13]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[14]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[15]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[16]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[17]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[18]  M. Weller,et al.  APO2 ligand: a novel lethal weapon against malignant glioma? , 1998, FEBS letters.

[19]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[20]  J. Dichgans,et al.  Topoisomerase‐I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl‐2 expression and of CD95‐mediated apoptosis by camptothecin and β‐lapachone , 1997, International journal of cancer.

[21]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[22]  J. Schulz,et al.  Adenoviral (Full-Length) Apo2L/TRAIL Gene Transfer is an Ineffective Treatment Strategy for Malignant Glioma , 2004, Journal of Neuro-Oncology.

[23]  Smac agonists sensitize for Apo 2 L / TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Reviews Cancer.

[24]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[25]  M. Weller,et al.  Human astrocytic brain tumors express APO2L/TRAIL , 1999, Acta Neuropathologica.